Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
about
Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidenceA randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis.Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.Pharmacokinetic Drug-Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese MenEvaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).Vonoprazan fumarate for the management of acid-related diseases.The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients.Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.Hypergastrinemia in Long-Term Use of Proton Pump Inhibitors.A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.Immune thrombocytopenia induced by vonoprazan fumarate: a single center retrospective study.Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin.Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors.Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis.Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers.Study for every other day administration of vonoprazan in maintenance treatment of erosive GERD: study protocol for a multicentre randomised cross-over study.Comment on "First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin".Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis.A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD).Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease.Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.Severity of gastric mucosal atrophy affects the healing speed of post-endoscopic submucosal dissection ulcers.Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use.
P2860
Q28072552-79C685FA-2645-400E-B341-53BBC58B480DQ33656886-5B20E63F-64D3-4CA5-8F38-675640648099Q36369941-0FE2128C-62D2-407F-B881-B7255C7FB1D8Q37553533-EC587DC2-9E10-416A-90D2-DB0608A692CCQ38381807-789C6BB9-8310-4439-B044-0D842C6C1286Q38599606-E3B26707-2167-4FD1-8F52-507891760612Q38861693-557154E2-FDA2-4839-AE37-28CA32F94901Q39402205-0AAF594D-451C-4E2C-BCA0-834FFBA95F45Q40153376-A1333229-F275-4C4B-8CB6-CE13686E4725Q40555482-B20B58EC-BF7C-4D4A-97FE-65331B776033Q40572311-1D526328-92F3-49C7-BB49-D2796B6E92AFQ40672521-04CBCC5B-D6F5-4802-8CBE-B781E29AD3ECQ47197069-5638724D-8AE6-48FC-BD1F-2CB8FDEA5842Q48099127-26F225F3-BCD0-4977-81F6-7EE73305E825Q48106665-AABCB202-B95A-4F98-8BA3-5970543541B6Q48339888-A2AA3188-5024-4654-B192-BB76D253482DQ49355765-2E204495-3AF4-4DEC-8165-A5209C874C10Q49447901-EEFB4628-A56C-4F6F-BCFF-2BBF4B415CCBQ49502751-DADF5F53-21CC-46E4-8033-DCC79B1B3D51Q49546655-2486D877-580D-4230-8E50-A245DFD063ABQ49630186-A2196C52-E005-4814-8633-59A5D9027A36Q49727148-EB20F1E4-D093-432D-9516-3CEF7E7FA113Q50129556-FB856F8C-4419-43B9-A12D-24AC39185C07Q50137013-5780214F-6FE1-4B69-BA21-8DD889E1F977Q51741477-C7892A44-F6DF-44E9-8B68-4F58454697DCQ52575016-D98A9945-F7E0-4878-91B7-307989AB67E9Q53511062-72A51CE6-563B-4E6F-8074-DB594FCC7530Q53731083-B4750E88-2183-4CE1-84CF-A688F1804F5CQ54388629-C38254C0-47A2-45BF-99AF-916AED83FDFEQ55128019-0AF4DEEF-16CF-495E-B3FD-7FE6E14ADA2CQ55248755-97855891-F4C2-4A46-9E6B-C344917DB9BCQ55493690-E4E2C960-1C5A-4FF3-A409-5130F8386967
P2860
Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Randomised clinical trial: von ...... aling of erosive oesophagitis.
@ast
Randomised clinical trial: von ...... aling of erosive oesophagitis.
@en
type
label
Randomised clinical trial: von ...... aling of erosive oesophagitis.
@ast
Randomised clinical trial: von ...... aling of erosive oesophagitis.
@en
prefLabel
Randomised clinical trial: von ...... aling of erosive oesophagitis.
@ast
Randomised clinical trial: von ...... aling of erosive oesophagitis.
@en
P2093
P2860
P356
P1476
Randomised clinical trial: von ...... aling of erosive oesophagitis.
@en
P2093
A Nishimura
N Hiramatsu
P2860
P304
P356
10.1111/APT.13461
P407
P577
2015-11-11T00:00:00Z